🕵️ Zevra Therapeutics, Inc. ($ZVRA)
SEC insider & ownership activity, last 12 months · CIK 1434647 · every row links its SEC filing
Over the last 12 months insiders sold $2.5M with no open-market buying against it. Neil F. McFarlane sold $1.2M through a 10b5-1 trading plan in 3 lots (Oct–Feb). 1 planned sale is pending, the largest $156K (John Bode). No red-flag 8-Ks in the window.
🚨 1 signal active —
planned-vs-executed verdicts, pre-event flags, and cluster context live in the
API and the
alerts bot.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
0 buyers, $0 (0 lots) · 6 sellers, $2.5M (13 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Neil F. McFarlane | 0 | – | 3 | $1.2M | Feb 9, 2026 |
| Thompson Rahsaan | 0 | – | 4 | $969K | Aug 14, 2026 |
| Watton Corey Michael | 0 | – | 1 | $138K | Aug 10, 2026 |
| Joshua Schafer | 0 | – | 2 | $126K | Feb 3, 2026 |
| Timothy J. Sangiovanni | 0 | – | 2 | $43K | Feb 3, 2026 |
| Adrian Quartel | 0 | – | 1 | $40K | Jan 30, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| FMR LLC | 8.3% | 13G | Aug 6, 2026 | filing ↗ | |
| Abigail P. Johnson | 8.3% | 13G | Aug 6, 2026 | filing ↗ | |
| Woodline Partners LP | 8.1% | 13G | Aug 14, 2026 | filing ↗ | |
| BlackRock, Inc. | 7.6% | 13G | Feb 5, 2025 | filing ↗ | |
| Vanguard Capital Management | 5.1% | 13G | Jul 31, 2026 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Rahsaan Thompson | $477K | Aug 14, 2026 | filing ↗ |
| John Bode | $156K | Jul 8, 2026 | filing ↗ |
| Rahsaan Thompson | $405K | May 11, 2026 | filing ↗ |
| Raymond L. Clifton | $3.4M | Mar 16, 2026 | filing ↗ |
| Neil F. McFarlane | $951K | Feb 2, 2026 | filing ↗ |
| Timothy Sangiovanni | $42K | Jan 30, 2026 | filing ↗ |
| R. LaDuane Clifton | $124K | Jan 30, 2026 | filing ↗ |
| Rahsaan Thompson | $36K | Jan 30, 2026 | filing ↗ |
| Joshua Schafer | $123K | Jan 30, 2026 | filing ↗ |
| Adrian Quartel | $40K | Jan 30, 2026 | filing ↗ |
| Neil F. McFarlane | $211K | Oct 10, 2025 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Earnings (2.02) | Aug 5, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 5, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 4, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 4, 2026 | filing ↗ |
| Earnings (2.02) | May 6, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 6, 2026 | filing ↗ |
| Material agreement (1.01) | Mar 12, 2026 | filing ↗ |
| Agreement terminated (1.02) | Mar 12, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Mar 12, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 12, 2026 | filing ↗ |
| Earnings (2.02) | Mar 4, 2026 | filing ↗ |
| Officer/director changes (5.02) | Mar 4, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 4, 2026 | filing ↗ |
| Officer/director changes (5.02) | Dec 11, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Dec 11, 2025 | filing ↗ |
| Officer/director changes (5.02) | Nov 26, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Nov 26, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 26, 2025 | filing ↗ |
| Officer/director changes (5.02) | Nov 20, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Nov 20, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 20, 2025 | filing ↗ |
| Earnings (2.02) | Nov 5, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 5, 2025 | filing ↗ |